Overview

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant effect than treatment with sertraline alone.
Phase:
Phase 3
Details
Lead Sponsor:
Hadassah Medical Organization
Collaborator:
Stanley Medical Research Institute
Treatments:
Sertraline